Due to a lack of data on clinical outcomes, the interim evaluation was unable to investigate whether Pilot participation affected clinical outcomes (e.g., diabetes, hypertension)
Initial effects typically manifest within the first week
Sumikawa, M
1 How it works The design of orforglipron emphasizes stability in the GI tract, which allows oral dosing while preserving target engagement
Drug Manufacturers During the model pre-implementation period in early 2026, CMS negotiated with Novo Nordisk and Eli Lilly to come to agreement on the key parameters of the model, including details about pricing of the model drugs, cost sharing, rebate calculations, access policies (i.e., coverage criteria and prior authorization policies), the length of the agreement, data sharing arrangements, and agreement on lifestyle supports that will be offered